Latest News

Reduction in Parkinson OFF Episodes Through Subcutaneous Apomorphine Infusion Leads to Doubling of Good ON Time
Reduction in Parkinson OFF Episodes Through Subcutaneous Apomorphine Infusion Leads to Doubling of Good ON Time

July 3rd 2025

Continuous subcutaneous apomorphine infusion significantly reduces OFF episodes and enhances ON time in Parkinson's disease patients, improving overall health status.

FDA Action Update, June 2025: Approval, Acceptance, Expanded Indication
FDA Action Update, June 2025: Approval, Acceptance, Expanded Indication

July 3rd 2025

Kara Keilman, PharmD, senior medical science liaison at Lundbeck
Post Hoc Analysis Highlights Brexpiprazole’s Efficacy and Tolerability in Alzheimer Agitation

July 2nd 2025

Long-Term 4-Year Data Highlights Sustained Effects of Deramiocel in DMD Cardiomyopathy
Long-Term 4-Year Data Highlights Sustained Effects of Deramiocel in DMD Cardiomyopathy

July 2nd 2025

Coverage of SLEEP 2025

Get direct access to interviews with experts, straight from the conference floor in Seattle, as well as the latest data and clinical news updates.

SLEEP 2025

Conference Coverage

View All
Reduction in Parkinson OFF Episodes Through Subcutaneous Apomorphine Infusion Leads to Doubling of Good ON Time
Reduction in Parkinson OFF Episodes Through Subcutaneous Apomorphine Infusion Leads to Doubling of Good ON Time

July 3rd 2025

Pamela Zeilman, NP
Revisiting Deep Brain Stimulation in a Pediatric-Onset Dystonia Case: Pamela Zeilman, NP

July 3rd 2025

Kara Keilman, PharmD, senior medical science liaison at Lundbeck
Post Hoc Analysis Highlights Brexpiprazole’s Efficacy and Tolerability in Alzheimer Agitation

July 2nd 2025

Video Series
Video Interviews
Podcasts

Most Recent

© 2025 MJH Life Sciences

All rights reserved.